HMGB1 is a Potential and Challenging Therapeutic Target for Parkinson's Disease

Overview

Journal Cell Mol Neurobiol

Publisher Springer

Specialties Cell Biology
Molecular Biology
Neurology

Date 2021 Nov 19

PMID 34797463

Citations 5

Authors

Yu Tian

Rong Chen

Zhaoliang Su

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is one of the most common degenerative diseases of the human nervous system and has a wide range of serious impacts on human health and quality of life. Recently, research targeting high mobility group box 1 (HMGB1) in PD has emerged, and a variety of laboratory methods for inhibiting HMGB1 have achieved good results to a certain extent. However, given that HMGB1 undergoes a variety of intracellular modifications and three different forms of extracellular redox, the possible roles of these forms in PD are likely to be different. General inhibition of all forms of HMGB1 is obviously not ideal and has become one of the biggest obstacles in the clinical application of targeting HMGB1. In this review, pure mechanistic research of HMGB1 and in vivo research targeting HMGB1 were combined, the effects of HMGB1 on neurons and immune cell responses in PD are discussed in detail, and the problems that need to be focused on in the future are addressed.

Citing Articles

Targeting the Sirtuin-1/PPAR-Gamma Axis, RAGE/HMGB1/NF-κB Signaling, and the Mitochondrial Functions by Canagliflozin Augments the Protective Effects of Levodopa/Carbidopa in Rotenone-Induced Parkinson's Disease.

Elkady M, Kabel A, Dawood L, Helal A, Borg H, Atia H Medicina (Kaunas). 2024; 60(10).

PMID: 39459469 PMC: 11509249. DOI: 10.3390/medicina60101682.

Endogenous Ligands of TLR4 in Microglia: Potential Targets for Related Neurological Diseases.

Chen B, Di B Curr Drug Targets. 2024; 25(14):953-970.

PMID: 39234911 DOI: 10.2174/0113894501316051240821060249.

Contrastive machine learning reveals Parkinson's disease specific features associated with disease severity and progression.

Zheng L, Zhou C, Mao C, Xie C, You J, Cheng W Commun Biol. 2024; 7(1):954.

PMID: 39112797 PMC: 11306336. DOI: 10.1038/s42003-024-06648-x.

QHRD106 ameliorates ischemic stroke injury as a long-acting tissue kallikrein preparation.

Xu S, Jia J, Sun M, Bao X, Xia S, Shu S iScience. 2023; 26(7):107268.

PMID: 37496671 PMC: 10366503. DOI: 10.1016/j.isci.2023.107268.

Repetitive transcranial magnetic stimulation alleviates glial activation through suppressing HMGB1/TLR4 pathway in a rat model of Parkinson's disease.

Han C, Zhang X, Dou K, Yao W, Yao M, Wan Q Mol Biol Rep. 2023; 50(8):6481-6492.

PMID: 37328582 PMC: 10374852. DOI: 10.1007/s11033-023-08561-8.

References

Nishibori M, Mori S, Takahashi H . Anti-HMGB1 monoclonal antibody therapy for a wide range of CNS and PNS diseases. J Pharmacol Sci. 2019; 140(1):94-101. DOI: 10.1016/j.jphs.2019.04.006. View

Wolf Y, Shemer A, Levy-Efrati L, Gross M, Kim J, Engel A . Microglial MHC class II is dispensable for experimental autoimmune encephalomyelitis and cuprizone-induced demyelination. Eur J Immunol. 2018; 48(8):1308-1318. DOI: 10.1002/eji.201847540. View

Wang C, Kao T, Lo W, Yen G . Glycyrrhizic acid and 18β-glycyrrhetinic acid modulate lipopolysaccharide-induced inflammatory response by suppression of NF-κB through PI3K p110δ and p110γ inhibitions. J Agric Food Chem. 2011; 59(14):7726-33. DOI: 10.1021/jf2013265. View

Lindersson E, Hojrup P, Gai W, Locker D, Martin D, Jensen P . alpha-Synuclein filaments bind the transcriptional regulator HMGB-1. Neuroreport. 2004; 15(18):2735-9. View

Shimoji M, Pagan F, Healton E, Mocchetti I . CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease. Neurotox Res. 2009; 16(3):318-28. DOI: 10.1007/s12640-009-9076-3. View

Clarkson B, Walker A, Harris M, Rayasam A, Sandor M, Fabry Z . CCR2-dependent dendritic cell accumulation in the central nervous system during early effector experimental autoimmune encephalomyelitis is essential for effector T cell restimulation in situ and disease progression. J Immunol. 2014; 194(2):531-41. PMC: 4362728. DOI: 10.4049/jimmunol.1401320. View

Hoppe G, Talcott K, Bhattacharya S, Crabb J, Sears J . Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1. Exp Cell Res. 2006; 312(18):3526-38. DOI: 10.1016/j.yexcr.2006.07.020. View

Subramaniam S, Napolitano F, Mealer R, Kim S, Errico F, Barrow R . Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia. Nat Neurosci. 2011; 15(2):191-3. PMC: 3267880. DOI: 10.1038/nn.2994. View

Musumeci D, Roviello G, Montesarchio D . An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther. 2013; 141(3):347-57. DOI: 10.1016/j.pharmthera.2013.11.001. View

10.

Huttunen H, Fages C, Rauvala H . Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem. 1999; 274(28):19919-24. DOI: 10.1074/jbc.274.28.19919. View

11.

Lu B, Wang C, Wang M, Li W, Chen F, Tracey K . Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review. Expert Rev Clin Immunol. 2014; 10(6):713-27. PMC: 4056343. DOI: 10.1586/1744666X.2014.909730. View

12.

Tian Y, Cao Y, Chen R, Jing Y, Xia L, Zhang S . HMGB1 A box protects neurons by potently inhibiting both microglia and T cell-mediated inflammation in a mouse Parkinson's disease model. Clin Sci (Lond). 2020; 134(15):2075-2090. DOI: 10.1042/CS20200553. View

13.

Trinh J, Zeldenrust F, Huang J, Kasten M, Schaake S, Petkovic S . Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord. 2018; 33(12):1857-1870. DOI: 10.1002/mds.27527. View

14.

Venezia S, Refolo V, Polissidis A, Stefanis L, Wenning G, Stefanova N . Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy. Mol Neurodegener. 2017; 12(1):52. PMC: 5496237. DOI: 10.1186/s13024-017-0195-7. View

15.

Bagheri V, Khorramdelazad H, Hassanshahi G, Moghadam-Ahmadi A, Vakilian A . CXCL12 and CXCR4 in the Peripheral Blood of Patients with Parkinson's Disease. Neuroimmunomodulation. 2018; 25(4):201-205. DOI: 10.1159/000494435. View

16.

Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, Qiang X . Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med. 2003; 9(1-2):37-45. PMC: 1430376. View

17.

Depboylu C, Stricker S, Ghobril J, Oertel W, Priller J, Hoglinger G . Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Exp Neurol. 2012; 238(2):183-91. DOI: 10.1016/j.expneurol.2012.08.020. View

18.

Teismann P, Sathe K, Bierhaus A, Leng L, Martin H, Bucala R . Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiol Aging. 2012; 33(10):2478-90. PMC: 3712169. DOI: 10.1016/j.neurobiolaging.2011.12.006. View

19.

Li Y, Niu M, Zhao A, Kang W, Chen Z, Luo N . CXCL12 is involved in α-synuclein-triggered neuroinflammation of Parkinson's disease. J Neuroinflammation. 2019; 16(1):263. PMC: 6909602. DOI: 10.1186/s12974-019-1646-6. View

20.

Lv R, Du L, Liu X, Zhou F, Zhang Z, Zhang L . Rosmarinic acid attenuates inflammatory responses through inhibiting HMGB1/TLR4/NF-κB signaling pathway in a mouse model of Parkinson's disease. Life Sci. 2019; 223:158-165. DOI: 10.1016/j.lfs.2019.03.030. View